Compare CFFN & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFFN | CMPS |
|---|---|---|
| Founded | 1893 | 2020 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2010 | 2020 |
| Metric | CFFN | CMPS |
|---|---|---|
| Price | $9.10 | $11.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 8 |
| Target Price | $7.25 | ★ $25.38 |
| AVG Volume (30 Days) | 793.2K | ★ 4.2M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 4.51% | N/A |
| EPS Growth | ★ 79.31 | N/A |
| EPS | ★ 0.32 | N/A |
| Revenue | ★ $16,300,000.00 | N/A |
| Revenue This Year | $20.16 | N/A |
| Revenue Next Year | $6.62 | N/A |
| P/E Ratio | $27.63 | ★ N/A |
| Revenue Growth | ★ 6.54 | N/A |
| 52 Week Low | $5.72 | $3.97 |
| 52 Week High | $9.10 | $15.40 |
| Indicator | CFFN | CMPS |
|---|---|---|
| Relative Strength Index (RSI) | 71.35 | 42.95 |
| Support Level | $7.49 | $10.72 |
| Resistance Level | N/A | $14.92 |
| Average True Range (ATR) | 0.23 | 0.78 |
| MACD | 0.02 | -0.14 |
| Stochastic Oscillator | 79.41 | 19.95 |
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
Compass Pathways PLC is a biotechnology company focused on developing therapies for mental health conditions. Its research centers on a proprietary synthetic psilocybin formulation, COMP360, which is administered alongside psychological support. The company is conducting clinical trials to evaluate the safety and efficacy of this treatment in patients with treatment-resistant depression and other mental health disorders. The company operates in one operating segment.